Tenecteplase Thrombolytic Therapy for Acute Ischemic Stroke in China

Summary

The objective of the study is to investigate the effectiveness and safety of rhTNK-tPA in acute ischemic stroke patients within 4.5 hours of symptom onset in a real-world clinical setting.

Conditions

• Ischemic Stroke

Interventions

DRUG

Tenecteplase

Thrombolysis wtih rhTNK-tPA

DRUG

Alteplase

Thrombolysis wtih rt-PA

Sponsors & Collaborators

• Keshiketeng Banner Traditional Chinese Medicine Mongolian Medicine Hospitalorem Ipsum

  collaborator UNKNOWN

• Nanshi Hospital of Nanyang

  collaborator UNKNOWN

• First Affiliated Hospital of Ningbo University

  collaborator NETWORK

• Jilin Liuhe Hospital

  collaborator UNKNOWN

• Shenyang Fifth People's hospital

  collaborator UNKNOWN

• Shanghai East Hospita

  collaborator UNKNOWN

• Shanghai 10th People's Hospital

  collaborator OTHER

• Shanghai Fifth People's Hospital

  collaborator UNKNOWN

• Shanghai Pudong Gongli hospital

  collaborator UNKNOWN

• Shanghai Neuromedical Center

  collaborator UNKNOWN

• Shanghai Fourth People's Hospital

  collaborator UNKNOWN

• Shanghai Pudong People's Hospital

  collaborator UNKNOWN

• Shanghai Putuo District Center Hospital

  collaborator OTHER

• Shenyang Fushun general hospital of mining bureau

  collaborator UNKNOWN

• Yantai Affliated Hosiptal of Binzhou Medical University

  collaborator UNKNOWN

• Shanghai Ninth People's Hospital Huangpu Branch

  collaborator UNKNOWN

• Shanghai Deji Hospital

  collaborator UNKNOWN

• Ruijin Hospital Luwan Branch

  collaborator OTHER

• Huashan Hospital

  lead OTHER

Principal Investigators

• Qiang Dong · Huashan Hospital

Eligibility

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2023-04-02

Primary Completion

2023-12-01

Completion

2024-05-01

Countries

• China

Study Locations